R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo Ramella Munhoz,Sandra P. D'Angelo,Sandra P. D'Angelo,Mrinal M. Gounder,Mrinal M. Gounder,Mary Louise Keohan,Mary Louise Keohan,Ping Chi,Ping Chi,Richard D. Carvajal,Samuel Singer,Samuel Singer,Aimee M. Crago,Aimee M. Crago,Jonathan Landa,Jonathan Landa,John H. Healey,John H. Healey,Li-Xuan Qin,Li-Xuan Qin,Meera Hameed,Meera Hameed,Marietta O. Ezeoke,Arun S. Singh,Mark Agulnik,Bartosz Chmielowski,Jason J. Luke,Brian A. Van Tine,Gary K. Schwartz,William D. Tap,William D. Tap,Mark A. Dickson,Mark A. Dickson +32 more
TL;DR: GDP combination used in the neoadjuvant setting resulted in significant toxicity; despite pathologic responses, no objective responses occurred.
Journal ArticleDOI
64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
Joseph J. Sacco,Richard D. Carvajal,Marcus O. Butler,Alexander N. Shoushtari,Jessica C. Hassel,A. Ikeguchi,Leonel Hernandez-Aya,Paul Nathan,Omid Hamid,J.M. Piulats Rodriguez,Matthew J. Rioth,Douglas B. Johnson,Jason J. Luke,Enrique Espinosa,Serge Leyvraz,H.M. Goodall,C. Holland,Shaad Essa Abdullah,Takami Sato +18 more
Journal ArticleDOI
Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
Amita Patnaik,Richard D. Carvajal,Kimberly M. Komatsubara,Carolyn D. Britten,Robert Wesolowski,Glenn Michelson,Oscar Alcantar,Chao Zhang,Ben Powell,Paul Severson,Eric J. Martin,Marlana Orloff +11 more
TL;DR: PLX51107 is an orally active small molecule inhibitor that exhibits low nanomolar potency in blocking interactions mediated by the four BET family proteins and a unique pharmacokine.
Journal ArticleDOI
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M. Hyman,Alexandra Snyder,Richard D. Carvajal,John F. Gerecitano,Martin H. Voss,Alan L. Ho,Jason A. Konner,Jennifer L. Winkelmann,Megan Stasi,Kelsey R. Monson,Alexia Iasonos,David R. Spriggs,Philip A. Bialer,Mario E. Lacouture,Jerrold B. Teitcher,Nora Katabi,Matthew G. Fury +16 more
TL;DR: The addition of buparlisib to carboplatin + paclitaxel was well tolerated, and preliminary activity was notable against tumors with loss of PTEN expression.
Journal ArticleDOI
Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
Scott N. Gettinger,Leora Horn,Leena Gandhi,David R. Spigel,Scott J. Antonia,Naiyer A. Rizvi,J.D. Powderly,Rebecca S. Heist,Richard D. Carvajal,David M. Jackman,L.V. Sequist,David Smith,P.D. Leming,Suzanne L. Topalian,F.S. Hodi,Mario Sznol,Christopher T. Harbison,Georgia Kollia,Julie R. Brahmer +18 more
TL;DR: This research was funded by Novartis, Pfizer, Ariad, Chugai, Genentech, Boehringer-Ingelheim and other sources.